Journal of Chemotherapy · 2005 · 29 citations · 20 references
MedicineOncologyPharmacotherapyBone MetabolismPain ManagementPain MedicineAnalgesiaBone Metabolism PharmacotherapyBone MetastasisMetastatic Bone DiseaseMetastatic Disease TreatmentProstate CancerAnalgesic Dose-response RelationshipsAnalgesic EffectsBone Metastases ManagementBone Metastasis Pain ControlBone Metastasis Response AssessmentBone Metastasis TherapyBone Pain In CancerMetastatic Bone Disease Management
Zoledronic acid is a bisphosphonate that is effective in the treatment of complications of metastatic bone disease. We have carried out a perspective study on 24 consecutive patients with prostate cancer metastatic to bone to verify the effect of zoledronic acid on analgesic response and a possible relationship with the levels of bone metabolism biomarkers. Eligibility for this study required prostate cancer patients with metastatic bone disease and pain not controlled by analgesics. Patients were excluded from the study if they were receiving cytotoxic chemotherapy or radiation therapy within three months. Eighteen patients (75%) were considered responder to acid zoledronic, only 6 patients did not respond. Before starting treatment (T0) mean Visual Analogue Scale was 7.8 (SE +/- 0.29), after 1 month therapy (T1) was 3.6 (SE +/- 0.3) and after three months (T2) was 3.1 (SE +/- 0.4) with a significant difference between T0 and T1 (p<0.0005) and between T0 and T2 (p<0.0005). Visual Analogue Scale improvement was positively correlated with decrease of C-telopeptide and bone phosphatase alkaline (p<0.05) serum levels.
20
Ronald C. Serlin, Tito R. Mendoza, Yoshio Nakamura et al. · Pain · 1995 · 1.5K citations
Medicine, Oncology, Pain Management +13
F. Saad, D. M. Gleason, R. Murray et al. · JNCI Journal of the National Cancer Institute · 2004 · 1.2K citations
James E. Dunford, Keith Thompson, Fraser P. Coxon et al. · Journal of Pharmacology and Experimental Therapeutics · 2001 · 896 citations
Pierre Major, Alain Lortholary, Jeremy K. Hon et al. · Journal of Clinical Oncology · 2001 · 857 citations